Structural Abnormalities of the Central Retina in Neurofibromatosis Type 2

Beatrice Emmanouil a, b  Martin Wasik a, c  Peter Charbel Issa c, d  Dorothy Halliday a  Allyson Parry a  Srilakshmi M. Sharma c, d

a Neurofibromatosis Type 2 Unit, Department of Neurosciences, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; b Department of Psychology, Health and Professional Development, Oxford Brookes University, Oxford, UK; c Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; d Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

Keywords
Spectral domain optical coherence tomography · Neurofibromatosis type 2 · Retinal tufts · Retinal hamartoma · Genetic severity

Abstract
Introduction: This case-control study seeks to systematically characterize the central retinal findings in a large cohort of patients with neurofibromatosis type 2 (NF2) using spectral domain optical coherence tomography (SD-OCT) as well as the examination of the potential use of this technique as a diagnostic tool in NF2. Methods: Fifty-four patients with an NF2 diagnosis seen in a quaternary national service were age- and gender-matched to 55 controls from the normal population. Two masked assessors categorized SD-OCT images using predefined abnormalities: retinal tufts, epiretinal membrane (ERM) appearance, retinal hamartoma, and foveal contour. Specificity, sensitivity, and positive and negative predictive values were calculated for each retinal abnormality. Trends of retinal abnormalities with NF2 genetic severity groups (1. tissue mosaic; 2A. mild classic; 2B. moderate classic; and 3. severe) were investigated. Results: We found retinal abnormalities in 26 patients with NF2 (48%) and 2 control patients (4%); retinal tufts were the most common abnormality therein (43%) and were not seen in controls. The specificity and sensitivity of the graded abnormalities on OCT scans in NF2 were 96% and 48%, respectively, with a positive predictive value of 93%. In our cohort, retinal tufts had a specificity of 100%, a sensitivity of 43%, and a positive predictive value of 100%. Retinal hamartomas were seen only in NF2 patients (35% sensitivity and 100% specificity). ERMs had 96% specificity and 13% sensitivity. The proportion of patients with retinal abnormalities increased statistically significantly with NF2 genetic severity; all patients within the 3. severe genetic severity had an abnormal SD-OCT. Discussion/Conclusion: We present a systematic study of central retinal abnormalities in an NF2 population as seen on SD-OCT imaging. Our results show a high frequency of retinal abnormalities that are readily detected by SD-OCT imaging. The presence of retinal tufts may be a novel marker of NF2 with both high specificity and a positive predictive value for NF2, compared to other well-known ocular features of NF2, and may have a place in the NF2 diagnostic criteria.

© 2021 The Author(s). Published by S. Karger AG, Basel

Correspondence to: Srilakshmi M. Sharma, publicationqueries@yahoo.com

This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY) (http://www.karger.com/Services/OpenAccessLicense). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher.
Introduction

Neurofibromatosis type 2 (NF2) is an autosomal dominant single gene disorder which is due to sporadic and inherited pathogenic variants (PVs) of the NF2 gene on chromosome 22. The incidence of NF2 is reported to be as high as 1 in 25,000 individuals in 2 large population studies in Finland and England [1–4]. NF2 is primarily characterized by the development of vestibular schwannomas, as well as other schwannomas, meningiomas, and ependymomas [5].

The NF2 phenotype classically also includes several ocular features such as cataracts and retinal abnormalities: hamartomas of the retina with or without retinal pigment epithelial involvement, and epiretinal membranes (ERMs) [5–10]. Hamartomas are developmental malformations of the retina mainly involving the inner layers, while ERMs in NF2 are proliferations at the vitreoretinal interface seen in spectral domain optical coherence tomography (SD-OCT) as an irregular and hyperreflective layer of the inner limiting membrane [11]. In early studies of NF2, both retinal abnormalities were thought of as distinct entities. Since then, histopathologic studies of eyes from patients with NF2 have shown both abnormalities to predominantly originate from altered retinal Müller cells [12, 13]. This observation has led some researchers to postulate that some apparent ERMs in NF2 patients are a form of hamartoma [14].

In the past decade, ophthalmic practice has been enhanced by the use of SD-OCT. This is a noncontact diagnostic technique that produces in vivo cross-sectional images of the retina. The SD-OCT technology uses infrared light to render retinal images with very high resolution (<7 μm), allowing individual retinal layers and the vitreo-retinal interface to be seen [15]. Studies which have used SD-OCT imaging in patients with NF2 have been able to characterize retinal findings in greater detail and identify novel retinal abnormalities such as retinal tufts, which are projections of tissue extending from the inner retina into the vitreous [14, 16, 17]. Retinal tufts are thought to be either focal ERMs or small elevations of retinal tissue which have been termed subclinical hamartomas, due to their small size but have similar histopathologic origin, from glial cells [12, 17]. While the presence of retinal tufts has been recognized in small case series [12, 17], the frequency of retinal tufts in patients with NF2 has not been studied in larger patient groups.

Symptoms and signs relating to vestibular schwannomas are not always the presenting feature in NF2, even less so in children who more commonly manifest eye, skin, or neurological problems [18–21]. The detection of ocular features can aid in the clinical diagnosis of NF2 and prompt early genetic testing [21, 22]. The recent identification of numerous retinal abnormalities by SD-OCT [17], which were previously undetected by fundus photography, suggests that the retinal features of NF2 may be more common than previously thought. They are also more common in more severe NF2 genotypes, an effect captured by a validated genetic severity score for NF2 [14, 17, 23–27]. We set out to systematically characterize the retinal findings in a large cohort of patients with NF2 using SD-OCT and to determine the potential use of this technique as a diagnostic tool in NF2.

Materials and Methods

Study Design and Patient Selection

The Oxford University Hospitals NHS Trust is 1 of 4 national centres for the multidisciplinary care of all known patients with NF2 in England. All patients with NF2 within the south-west region of England are under the care of the NF2 service in Oxford.

This case-controlled study compared the SD-OCT findings of all patients with confirmed NF2 according to the Manchester criteria [28–30], who were consecutively seen in the Oxford University Hospitals ophthalmology clinic as part of their annual review between August 2016 and July 2017. Anonymized demographic data were collected, including age, gender, diagnosis, and NF2 genetic severity; the latter was assigned using the UK NF2 genetic severity score dividing the patients into groups: 1. tissue mosaic; 2A. mild classic; 2B moderate classic; and 3. severe [26]. Images of SD-OCTs of the eyes from age- and gender-matched healthy volunteers (these had been previously imaged and stored prior to the study, and were taken from a population with no known retinal disease or systemic disorders associated with retinal pathology) were used to serve as the control group.

SD-OCT Imaging

All patients underwent SD-OCT imaging through undilated pupils using the Spectralis HRA + OCT (Heidelberg Engineering, Heidelberg, Germany). A sequence of horizontal scans recorded in the high-speed mode (768 A-scans/30°) and covering an area of 30° (horizontal) × 15° (vertical) centred on the fovea, with approximately 120 μm between individual scans, was recorded.

Image Analysis

Two masked retinal specialists (SS and PCI) independently analysed SD-OCT scans of NF2 patients and healthy controls in a randomized order. The grey-scale SD-OCT images were viewed on a 22-inch liquid crystal display monitor (1,920 × 1,080 pixels) using HEYEY software (Heidelberg Engineering).

The assessors were asked to specify the overall appearance of the SD-OCT recordings and the presence or absence of the following qualitative variables: retinal hamartoma, ERM appearance, retinal tufts, and abnormal foveal contour. Examples of these features as demonstrated to the masked assessors (in a single training session) were derived from figures in a previous study of NF2-associ-
Central Retinal Abnormalities in Neurofibromatosis Type 2

**Table 1. Patient demographics**

|                        | NF2  | Control |
|------------------------|------|---------|
| Patients, n            | 54   | 55      |
| Eyes, n                | 101  | 110     |
| Age, years             |      |         |
| Mean                   | 37.9 | 37.2    |
| Standard deviation     | 19   | 15      |
| Gender, n (%)          |      |         |
| Male                   | 26 (48.1) | 27 (49.1) |
| Female                 | 28 (51.9) | 28 (50.9) |
| Genetic severity score, n (%) | | |
| 1 tissue mosaic        | 17 (31.5) | –       |
| 2A mild classic        | 10 (18.5) | –       |
| 2B moderate classic    | 14 (25.9) | –       |
| 3 severe               | 12 (22.2) | –       |

There were 63 patients with confirmed NF2 diagnosis of which 9 (11 eyes) were excluded, leaving 54 patients (101 eyes) whose demographics are shown in Table 1. Age- and gender-matched controls (N = 55, 110 eyes) were included for comparison. Case note review of the 54 included patients revealed that 48% had cataracts (19% bilateral), where cataract is a NF2 diagnostic criterion.

Figure 1 shows representative examples of the range and variation in retinal abnormalities observed on SD-OCT images of patients with NF2. Most images show isolated retinal tufts appearing as simple small projections above the internal limiting membrane, or larger two-or-more pronged formations often resembling horns or flames. The typical appearance of ERMs as commonly seen in other conditions (a single hyper-reflective sheet seen above the internal limiting membrane, often distorting its shape), was only rarely seen. Retinal hamartomas were seen quite commonly, and involved retinal thickening and disorganization, primarily of the inner layers extending involvement to the RPM in some of the cases.

The ability of SD-OCT to identify tufts that would otherwise likely have been missed on fundus examination is highlighted in Figure 2, where the only sign on the fundus photograph is a slightly abnormal light reflex.

Abnormal SD-OCTs were found in 26 patients with NF2 (48%) and 2 patients in the control population (4%) (Table 2). There was perfect inter-observer agreement (k = 1.0) between the 2 masked assessors for all retinal abnormalities identified, and therefore, arbitration was not required. The only abnormalities found in the control group were ERMs and abnormal foveal contour; there were no control patients with retinal tufts or retinal hamartomas. Retinal tufts were seen in 23 patients with NF2 (43%), and retinal hamartomas were seen in 19 patients (35%). The odds ratio for an abnormal SD-OCT scan in patients with NF2 were significantly higher than those in the control group (OR = 24.6). All odds ratios were statistically significant (p < 0.05).

Within this cohort, we found that the presence of an SD-OCT abnormality was associated with at least a 96% specificity for NF2, although the sensitivity was lower at 48%. The positive predictive value was calculated as 100% for retinal tufts, supporting their potential as one of the clinical features of NF2. Negative predictive values for SD-OCT abnormalities (53–63%) indicate that the absence of any SD-OCT abnormalities does not exclude NF2.

Within the NF2 population, retinal tufts were the most frequently encountered abnormality, found in 23 patients (48%) (Table 3). Retinal hamartomas were seen in 19 patients (35%), and an abnormal foveal contour was seen in 12 patients (22%). Eighty-four percent of patients who had retinal hamartoma also had a retinal tuft detected in

**Exclusion Criteria**

SD-OCT images with a quality of index of <15 were excluded (these were patients with NF2 who had nystagmus or media opacities) [31]. Similarly, patients in whom we were unable to obtain an SD-OCT analysis due to physical disabilities were also excluded from the analysis. No images from the control group were excluded.

**Statistical Analysis**

SPSS 25 was used for all statistical analyses. We reported summary statistics throughout. Inferential statistical significance was set to p < 0.05. We calculated the Mantel-Haenszel common odds ratio estimates for each SD-OCT finding with asymptotic 95% confidence intervals for single strata design comparisons with balanced groups of NF2 and control patients and applied a 0.5 constant continuity correction to all cells in tables with zero events. Trends of increasing proportions of retinal abnormalities with genetic severity, as well as of increasing visual impairment with SD-OCT findings, were investigated using Mantel-Haenszel linear-by-linear $\chi^2$ tests of association. Associations between SD-OCT abnormalities were investigated using Pearson’s $\chi^2$ tests and Fisher’s exact tests. Multiple comparison corrections were applied.
their SD-OCT; 63% of patients who had retinal hamartoma also had abnormal foveal contour and 26% had ERMs. ERMs were observed in combination with other retinal tufts and retinal hamartomas 71% of the time.

When examining the occurrence of multiple retinal abnormalities within the same eye, retinal tufts were found to be the most frequent finding for any combination. Most eyes with an abnormal scan (45%) had 3 OCT abnormalities, with the most common combination (39%) being retinal tufts, retinal hamartoma, and foveal contour. Thirty-nine percent of affected eyes had only 1 abnormality, with the majority (32%) being retinal tufts. An abnormal foveal contour was always observed in combination with 2 or more other findings.

The relationship between retinal abnormalities and NF2 genetic severity was also examined. Within this cohort, the proportion of patients with retinal tufts, retinal hamartoma, or abnormal foveal contour increased in a

---

**Fig. 1.** Examples of SD-OCT images from patients with NF2 illustrating the various retinal abnormalities found. a ERM, combined retinal hamartoma (involving RPE), tuft. b Retinal hamartoma, tuft. c Retinal hamartoma, tuft. d ERM, retinal hamartoma, tuft. e Retinal hamartoma, tuft. SD-OCT, spectral domain optical coherence topography; ERM, epiretinal membrane; RPE, retinal pigment epithelium; NF2, neurofibromatosis type 2.
Central Retinal Abnormalities in Neurofibromatosis Type 2

Fig. 2. An illustration of the improved visibility of retinal abnormalities on SD-OCT compared to fundus examination. On the left: fundus colour photograph of a right eye from a NF2 patient. An only mildly abnormal retinal reflex is seen temporal to the fovea (highlighted). On the right: an SD-OCT raster image through the fovea of the eye depicted on the left, showing a small retinal tuft corresponding to the abnormal retinal reflex seen. SD-OCT, spectral domain optical coherence topography; NF2, neurofibromatosis type 2.

Table 2. Frequency of SD-OCT abnormalities in patients with NF2 and healthy controls

| SD-OCT finding       | Group               | Odds ratio | 95% CI     | Sensitivity, % | Specificity, % | Positive predictive value, % | Negative predictive value, % |
|----------------------|---------------------|------------|-------------|----------------|----------------|-----------------------------|------------------------------|
|                      | NF2 patients, (N = 54) |            |             |                |                |                             |                              |
|                      | control group, (N = 55) |            |             |                |                |                             |                              |
| Abnormal scan        | 26 (48)             | 2 (4)      | 24.6 (5.4, 111.3) | 48              | 96             | 93                          | 65                           |
| Retinal tuft         | 23 (43)             | 0 (0)      | 82.8 (4.9, 1,410.4) | 43              | 100            | 100                         | 64                           |
| Retinal hamartoma    | 19 (35)             | 0 (0)      | 61.0 (3.6, 1,042.1) | 35              | 100            | 100                         | 61                           |
| Abnormal foveal contour | 12 (22)          | 2 (4)      | 7.6 (1.6, 35.7) | 22             | 96             | 86                          | 56                           |
| ERM                  | 7 (13)              | 2 (4)      | 3.9 (0.8, 19.9)  | 13             | 96             | 78                          | 53                           |

Odd ratios (with 95% confidence intervals) for each SD-OCT qualitative variable in NF2 are shown, as well as the specificity, sensitivity, positive predictive value, and negative predictive value of each abnormality. ERM, epiretinal membrane; N, number of patients; SD-OCT, spectral domain optical coherence topography; NF2, neurofibromatosis type 2.

Table 3. Associations between retinal abnormalities in patients with NF2 demonstrating the frequency of retinal tufts in association with other abnormalities in patients with NF2

|                     | Retinal tuft, n (%) | Retinal hamartoma, n (%) | Abnormal foveal contour, n (%) | ERM, n (%) |
|---------------------|---------------------|---------------------------|-------------------------------|------------|
| Total patients (N = 54) | 23 (43)            | 19 (35)                   | 12 (22)                       | 7 (13)     |
| Retinal tuft (N = 23) (17 bilateral) | N/A                | 16 (84)**                 | 12 (100)**                    | 5 (71)     |
| Retinal hamartoma (N = 19) (9 bilateral) | 16 (70)**           | N/A                       | 12 (100)**                    | 5 (71)     |
| Abnormal foveal contour (N = 12) (6 bilateral) | 12 (52)**           | 12 (63)**                 | N/A                           | 1 (14)     |
| ERM (N = 7) (0 bilateral) | 5 (22)              | 5 (26)                    | 1 (8)                         | N/A        |

ERM, epiretinal membrane appearance; N, number of patients; NF2, neurofibromatosis type 2. ** Indicates a statistically significant association (p < 0.01).
statistically significantly manner with genetic severity. All patients within the severe NF2 genetic severity (group 3) had an abnormal SD-OCT; 7 of 14 patients (50%) in group 2B, 6 of 10 (60%) in group 2A, and 3 of 17 patients (18%) in group 1 had abnormal SD-OCTs (Fig. 3). ERM prevalence in NF2 was comparable across all genetic severity groups in this cohort. The variability in phenotype is reflected in the lower negative predictive values, as absence of retinal abnormalities in the milder genotype groups does not exclude NF2.

Discussion/Conclusion

Early diagnosis of NF2 is important to optimize management and allow timely intervention. The diagnosis of NF2 is frequently delayed [32], especially in children with severe de novo NF2, who typically present with symptoms and signs that are not related to a vestibular schwannoma [18–21]. The heterogeneous presenting clinical features of NF2 highlight the value in developing reliable biomarkers for NF2.

SD-OCT scans are noninvasive, rapidly acquired images capable of diagnosing and monitoring many retinal disorders, and are routinely performed in the community and in the hospital setting. For patients with NF2, it enables abnormalities within each retinal layer to be phenotyped with great accuracy. Retinal tufts may easily be missed on funduscopic examination or colour photography (Fig. 1) and were the most frequently occurring OCT-based retinal abnormality in this large NF2 cohort (43% NF2; 0% controls). In fact, it was rare to find an abnormal SD-OCT that did not include a retinal tuft (12% of abnormal scans). An inter-observer agreement of 100% between the 2 OCT-assessing ophthalmologists demonstrated the ease and accuracy of identification of retinal tufts.

Retinal tufts within NF2 are small, isolated proliferations of the glial tissue (focal ERMs) or discrete elevations of inner retinal tissues [12, 13]. The term “retinal tuft” has been used elsewhere to describe idiopathic peripheral cystic lesions whose morphology as seen on OCT is not dissimilar to the retinal tufts seen in NF2 [33]. However, to our knowledge, they have never been described within the macula region as retinal tufts but rather as probable astrocytic hamartomas [34]. The term, retinal tufts has been used for lesions in the far periphery of the retina [35].

We characterized the central retinal pathology in NF2 using SD-OCT imaging characteristics only, resulting in a number of differences from previous reports based upon clinical examination [7, 8, 14]. For example, ERMs were an infrequent finding in our study (13%), compared with previous fundus examinations on patients reported by Meyers et al. [8], where 12 of 15 patients had ERMs. It is likely that the patients reported in Meyers et al. [8] were of a more severe genotype. Other SD-OCT NF2 studies have classified SD-OCT findings in NF2 as either ERMs or retinal hamartomas while we have reported various anatomical changes of which the retinal tuft is 1 descriptor.

In our study, as well as in previous, retinal hamartomas were associated with more severe disease in NF2 [8, 10, 24, 32]. Of the 8 patients with CHRRPE, none belonged to the 1. tissue mosaic group and 5 of the 30 2B. moderate classic patients had a combined hamartoma. Also, there was no significant difference in the ages of the patients whose hamartoma involved the RPE and those whose
hamartoma was limited in the inner layers. While
CHRRPEs have been seen with NF2 in some studies [8,
16, 22], in others – especially involving larger groups of
patients – retinal hamartomas were observed to have
none, occasional, or very mild RPE involvement [10, 12,
16, 23, 24]. This is in line with our findings that suggest
that a smaller proportion of retinal hamartomas observed
using SD-OCT in NF2 are CHRRPEs. Of the 8 patients
who had CHRRPE 1 also had an ERM. Only 1 of 7 ERMs
was observed with a CHRRPE but 71% with a retinal
hamartoma that did not involve the RPE, which is in line
with previous observations of retinal hamartomas with
ERMs [16, 24].

Tuberous sclerosis, among other phakomatoses, also
causes subtle retinal hamartomas not seen in fundus ex-
amination [36]. However, their morphology is different
from that observed in NF2. Other isolated abnormalities
of astrocytic proliferation that we have identified in the
literature as being similar to the retinal tufts in our study
are still quite distinct and easily differentiated [37]. Astro-
cytic proliferations are more discrete, more raised, and
the shadowing on OCT that they produce obscures the
retinal layers in a way that tufts seen within our study do
not. Frequent bilateral involvement has also been associ-
ated with NF2 [9, 38], and this has been confirmed here-
in.

Although our sample size was small (54 patients and
55 controls), these preliminary data suggest that retinal
tufts have a higher sensitivity in NF2 than any other ocu-
ar feature herein. Forty-eight percent (30% unilateral)
of patients in this dataset had cataracts, a current diag-
nostic criterion, comparable to 43% with retinal tufts,
emphasising the importance of this retinal abnormality
in NF2 diagnosis. Twenty-eight percent of patients with
NF2 had both cataracts and retinal tufts, but only 5% had
bilateral cataracts and bilateral retinal tufts. Our data
show that the probability of an individual with a retinal
tuft or retinal hamartoma having NF2 was 100%; how-
ever, this is an overestimate as retinal hamartomas have
also been observed in other rare diseases [7, 8, 22, 27,
38–44]. An appropriately powered control group includ-
ing other ophthalmic diseases will be required to un-
equivocally establish sensitivity and specificity of retinal
tufts.

The presence of retinal tufts is not uniformly distrib-
uted among patients and is particularly indicative of a
severe genotype; expression increases with higher NF2
gene mutation severity scores, occurring with a 12% frequency
in group 1 tissue mosaic patients where there are no NF2
PVs in the blood and 100% frequency in group 3 severe
patients where there are truncating constitutional NF2
PVs. Although a negative result may not exclude NF2,
detection of retinal tufts may be especially important in
children with non-specific signs, such as amblyopia or a
cranial nerve palsy. We have previously found that oph-
thalmological findings are the most frequent first mani-
festations in paediatric onset NF2 [19]. In the manner
that detection of retinal hamartoma in children may lead
to a diagnosis of NF2 [22], retinal tufts may indicate eval-
uation for NF2 in a specialist clinic. NF2 can be diagnosed
with a variety of combinations of clinical features and the
current guidelines recommend follow-up for patients
with probable NF2 until diagnosis is possible or discharge
after a certain age when risk falls below 1% [45]. The pres-
ence of retinal tufts, if validated, may merit inclusion as a
diagnostic criterion. The identification of a structural ab-
normality on SD-OCT and in particular retinal tufts in
asymptomatic offspring of would suggest that a child had
inherited NF2 and may allow earlier diagnosis in cases
where presymptomatic genetic testing is not possible.
Furthermore, as all patients in group 3. severe had retinal
tufts, a normal SD-OCT may reduce the likelihood that a
child had inherited a severe NF2 [16]. However, we ac-
knowledge that the natural history of retinal tuft develop-
ment in the context of NF2 is not yet known.

Limitations in this study include the low sample size
due to the rarity of NF2. However, the magnitude of dif-
fference between NF2 and control groups affirms the va-
lidity of the findings of this study, which is the largest
OCT series reported in the NF2 population to date. A
larger control group and comparison with other associ-
ated disorders such as schwannomatosis or NF1 will be
necessary to accurately define the diagnostic value of reti-

nal tufts. Media opacities within the eye such as dense
cataracts and corneal scarring or ocular motility disorders
such as nystagmus hamper the feasibility of OCT imag-
ing, making it unsuitable for a small proportion of pa-
ients, potentially leading to an underestimate of retinal
findings since poor vision is usually associated with worse
genic severity [14, 17, 23–27]. We only obtained SD-
OCT scans through the macula; while the majority of
studies in NF2 report retinal abnormalities predominant-
ly in the macula region, there are reports of retinal ham-
artomas in the peripheral retina in patients with NF2 [8,
46], which would not have been detected in our study
potentially further underestimating the frequency of reti-
nal abnormalities in this patient group. Furthermore,
scanning the central retina only could potentially miss
other structures in the extramacular retina such as vitreoretinal bands or posterior vitreous remnants which might
be seen in non-NF2 populations. Wide-field retinal SD-OCT may be valuable in the evaluation of retinal findings in NF2 [47].

In summary, we present the largest SD-OCT study to date, to detect retinal abnormalities in NF2. Our results indicate a high frequency of retinal abnormalities, readily detected by SD-OCT. We propose that using SD-OCT, rather than fundus photography, will allow accurate phenotyping of retinal abnormalities in NF2, and with less ambiguity than with clinical examination alone. This may have particular benefit in avoiding delayed diagnosis in children. Retinal tufts at the macula appear to be rapidly identifiable, common features of NF2, with high specificity, suggesting a possible role for this feature as a novel diagnostic marker of NF2.

Acknowledgements

The authors would like to thank the patients and the NF2 team. In particular, they would like to thank Rosie Crabtree, Carolyn Redman, Gillian Hemmings, Wendy Howard, Monisha Rahman, Youssef Sida, Kate Browne, and Rachel Woolrich.

Statement of Ethics

The study was approved and registered as a service evaluation (ref: 091216-NOTSS-ASLAM) at Oxford University Hospitals NHS Foundation Trust, and all procedures undertaken in the study were in accordance with the 1964 Helsinki Declaration. As there was no active human participation in this study (this is a retrospective, anonymized review of routinely collected clinical data), no informed consent was deemed necessary by the health research authority. Ethical approval was not sought because clinical audits in UK are subject to different guidance in accordance with the National Research Ethics Service (2009), thus exempting the work from the need for ethical approval [48].

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

Financial support: PCI was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), Oxford, United Kingdom; SMS receives funding from MRC UK (Grant No.: MR/T024682/1).

Author Contributions

B.E. substantially contributed to the design of the work, the acquisition, analysis, and interpretation of data for the work as well as the drafting of the work and revision for critically important intellectual content; M.W. substantially contributed to the concept and design of the work, the acquisition, and interpretation of data for the work as well as the drafting of the work; P.C.I. substantially contributed to the acquisition and interpretation of data for the work as well as the revision for critically important intellectual content; D.H. substantially contributed to the design of the work, the interpretation of data for the work as well as the revision for critically important intellectual content; A.P. substantially contributed to the design of the work, the interpretation of data for the work as well as the revision for critically important intellectual content; S.M.S. substantially contributed to the design of the work, the interpretation of data for the work as well as revision for critically important intellectual content. All authors gave final approval of the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Data Availability Statement

We cannot share any raw anonymized data due to the small numbers of patients in our study and the rarity of the disease. We will consider requests for aggregate data on an individual basis.

References

1. Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A(2):327–32.
2. Evans DG, Bowers NL, Tobin S, Hartley C, Wallace AJ, King AT, et al. Schwannomatosis: a genetic and epidemiological study. J Neurol Neurosurg Psychiatry. 2018;89(11):1215–9.
3. Antinheimo J, Sankila R, Carpén O, Pukkala E, Sainio M, Jääskeläinen J. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology. 2000;54(1):71–6.
4. Evans DG, Moran A, King A, Saeed S, Gurusininghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the north west of England over a 10-year period: higher incidence than previously thought. Otol Neurotol. 2005;26(1):93–7.
5. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, et al. A clinical study of type 2 neurofibromatosis. Q J Med. 1992;84(304):603–18.
6. Bosch MM, Boltshauser E, Harpes P, Landau K. Ophthalmologic findings and long-term course in patients with neurofibromatosis type 2. Am J Ophthalmol. 2006;141(6):1068–77.
7. Kaye LD, Rothner AD, Beauchamp GR, Meyers SM, Estes ML. Ocular findings associated with neurofibromatosis type II. Ophthalmology. 1992;99(9):1424–9.
8. Meyers SM, Gutman FA, Kaye LD, Rothner AD. Retinal changes associated with neurofibromatosis 2. Trans Am Ophthalmol Soc. 1995;93:245–7; discussion 52–7.
9. Landau K, Yaşargil GM. Ocular fundus in neurofibromatosis type 2. Br J Ophthalmol. 1993;77(10):646–9.
10. Ragge NK, Baser ME, Klein J, Nechiporuk A, Sainz J, Pulst SM, et al. Ocular abnormalities in neurofibromatosis 2. Am J Ophthalmol. 1995;120(5):634–41.
Central Retinal Abnormalities in Neurofibromatosis Type 2

Ophthalmic Res 2022;65:77–85
DOI: 10.1159/000519143

11 Hubschman JP, Govetto A, Spade RF, Schumann R, Steel D, Figueroa MS, et al. Optical coherence tomography-based consensus definition for lamellar macular hole. Br J Ophthalmol. 2020;104(12):1741–7.

12 Chan CC, Koch CA, Kaiser-Kupfer MI, Parry DM, Gutmann DH, Zhuang Z, et al. Loss of heterozygosity for the NF2 gene in retinal and optic nerve lesions of patients with neurofibromatosis 2. J Pathol. 2002;198(1):14–20.

13 McLaughlin ME, Pepin SM, MacCollin M, Choospang P, Lessell S. Ocular pathologic findings for neurofibromatosis type 2. Arch Ophthalmol. 2007;125(3):389–94.

14 Sisk RA, Berrocal AM, Scheffer AC, Dubovy SR, Bauer MS. Epiretinal membranes indicate a severe phenotype of neurofibromatosis type 2. Retina. 2010;30(4 Suppl):S51–8.

15 Nassif N, Cense B, Park B, Pierce M, Yun S, Bousma B, et al. In vivo high-resolution videoretape spectral-domain optical coherence tomography of the human retina and optic nerve. Opt Express. 2004;12(3):367–76.

16 Kang HM, Koh HJ, Chung EJ. Spectral-domain optical coherence tomography of combined hamartoma of the retina and retinal pigment epithelium in neurofibromatosis. Korean J Ophthalmol. 2013;27(1):68–71.

17 Waissberg V, Rodrigues LO, Nhemny MB, Frasson M, de Miranda DM. Spectral-domain optical coherence tomography findings in neurofibromatosis type 2. Invest Ophthalmol Vis Sci. 2016;57(9):OC726–7.

18 Ruggieri M, Iannetti P, Polizzi A, La Mantia I, Spalice A, Giliberto O, et al. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics. 2005;36(1):21–34.

19 Halliday D, Emmanouil B, Bassetto G, Lascelles K, Nicholson J, Chandratte S, et al. Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity. J Med Genet. 2019;56:463–9.

20 Ruggieri M, Praticò AD, Serra A, Maiolino L, Cocuzza S, Di Mauro P, et al. Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies. Acta Otorhinolaryngol Ital. 2016;36(5):345–67.

21 Anand G, Vassallo G, Lascelles K, Nicholson J, Chandratre S, et al. Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity. Clin Genet. 2019;96(2):151–62.

22 Grant EA, Trzupek KM, Reiss J, Crow K, Messier L, Webber RG. Combined retinal hamartomas leading to the diagnosis of neurofibromatosis type 2. Ophthalmic Genet. 2008;29(3):133–8.

23 Basr ME, Kluwe L, Mautner VF. Germ-line NF2 mutations and disease severity in neurofibromatosis type 2 patients with retinal abnormalities. Am J Hum Genet. 1999;64(4):1230–3.

24 Parry DM, MacCollin MM, Kaiser-Kupfer MI, Palaski K, Nicholson HS, Bolesta M, et al. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet. 1996;59(3):529–39.

25 Feucht M, Kluwe L, Mautner VF, Richard G. Correlation of nonsense and frameshift mutations with severity of retinal abnormalities in neurofibromatosis 2. Arch Ophthalmol. 2008;126(10):1376–80.

26 Halliday D, Emmanouil B, Pretorius P, MacKeith S, Painter S, Tomkins H, et al. Genetic severity score predicts clinical phenotype in NF2. J Med Genet. 2017;54(10):657–64.

27 Painter S, Sipkova Z, Emmanouil B, Halliday D, Parry A, Elston J. Neurofibromatosis type 2-related eye disease correlated with genetic severity. J Neuroophthalmol. 2019;39(1):44–9.

28 Smith MJ, Bowers NL, Bulman G, Gokhale C, Wallace AJ, King AT, et al. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LITZRI-related schwannomatosis. Neurology. 2017;88(1):87–92.

29 Gutmann DH, Alysworth A, Carey JC, Korf BR, Marks J, Peyeritz RE, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278(1):51–7.

30 Evans DG, Huson SM, Donnai D, Neary W, Pike M, Kariyawasam DS, et al. Diagnosis of sporadic neurofibromatosis type 2 (NF2) in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet. 1992;29(12):847–52.

31 Evans DG, Raymond FL, Barwell JG, Halliday CL. Combined hamartoma of the retina and retinal pigment epithelium of patients with neurofibromatosis type 2. J Med Genet. 1991;28:44–9.

32 Arepalli S, Pellegrini M, Ferencyz SR, Shields CL. Combined hamartoma of the retina and retinal pigment epithelium associated with neurofibromatosis type-1. Int Ophthalmol. 2001;24(2):63–6.

33 Evans DG, Raymond FL, Barwell JG, Halliday CL. Genetic testing and screening of individuals at risk of NF2. Clin Genet. 2012;82(3):416–24.

34 Bouzas EA, Parry DM, Eldridge R, Kaiser-Kupfer MI. Familial occurrence of combined pigment epithelial and retinal hamartomas associated with neurofibromatosis type 2. Retina. 1992;12(2):103–7.

35 Polans J, Keller B, Carrasco-Zevallos OM, LaRocca F, Cole E, Whitson HE, et al. Wide-field retinal optical coherence tomography with wavefront sensing adaptive optics for enhanced imaging of targeted regions. Biomed Opt Express. 2017;8(1):16–37.

36 Shields CL, Manalac J, Das C, Saktanasate J, Shields JA. Review of spectral domain-enhanced depth imaging optical coherence tomography of tumors of the retina and retinal pigment epithelium in children and adults. Indian J Ophthalmol. 2015;63(2):128–32.

37 Dedania VS, Ozgonul C, Zachs DN, Besirli CG. Novel classification system for combined hamartoma of the retina and retinal pigment epithelium. Retina. 2018;38(1):12–9.

38 Hubschman JP, Govetto A, Spade RF, Schumann R, Steel D, Figueroa MS, et al. Optical coherence tomography-based consensus definition for lamellar macular hole. Br J Ophthalmol. 2020;104(12):1741–7.

39 Shahid MK, Kluwe L, Mautner VF, Richard G. Correlation of nonsense and frameshift mutations with severity of retinal abnormalities in neurofibromatosis 2. Arch Ophthalmol. 2008;126(10):1376–80.

40 Polans J, Keller B, Carrasco-Zevallos OM, LaRocca F, Cole E, Whitson HE, et al. Wide-field retinal optical coherence tomography with wavefront sensing adaptive optics for enhanced imaging of targeted regions. Biomed Opt Express. 2017;8(1):16–37.

41 Available from: http://www.hrcdecisiontools.org.uk/research/